Patient Education Blog

Pradaxa – What Your Physician/Hospital Wants to Know

If you are considering to start therapy with the new oral “blood thinner” Pradaxa®, there are a few safety nets that your local hospital and physician may want to establish to make therapy as safe as possible for you. Issues to be addressed are (a) dosing, (b) management of major bleeding, (c) interruption of therapy for surgery, dental procedures, or other procedures, d) what to do if you missed a dose, and (e) what to do if the pill box has been left open for too long.

These issues are probably best addressed by the establishment of a treatment algorithm/guide/help for the whole hospital or physician practice.  As an example, attachedthat we developed for our institution, the University of North Carolina (UNC) Health Care System. Your physicians and pharmacists are free to (a) take the document and modify it to fit their institution/practice or (b) use it as a clinical reference for management issues.

Support Forum:  Questions or comments about Pradaxa and its use? Go to the online Clot Connect Support Forum, category “Anticoagulant Use (Blood Thinners)”.

For Health Care Professionals:  This same post, written for health care professionals, is posted here.

Disclosure: I have no financial conflict of interest relevant to this educational post.

Last updated: May 1st, 2012

Disclaimer:, its contributors, authors, advisors, members and affiliate organizations do not assume any liability for the content of the website, blog and educational materials. Medical information changes rapidly. While information is believed to be correct, no representation is made and no responsibility is assumed for the accuracy of information contained on or available through this web site and blog. Information is subject to change without notice. 

Tags: , , , , , , , , , ,

4 Responses to “Pradaxa – What Your Physician/Hospital Wants to Know”

  1. Jeffrey Ramsay says:

    I am a cardiac patient who has been unable to find out whether dabigatran is indicated for a patient with an artificial heart valve and a pacemaker. Could anyone help?

    • Stephan Moll says:

      As of June 7th, 2011, it is not. Dabigatran in the U.S. is only approved for atrial fibrillation (irregular heart beat). In a number of countries outside the U.S. Dabigatran is also approved for DVT prophyalxis after orthopedic surgery. However, nowhere is it approved for artifical heart valves. There are, at this point, no studies on such patients. In the absence of data on effectiveness, I would NOT use it off label for that indication.